Day One Biopharmaceuticals, Inc. (DAWN)
Largest Insider Buys in Sector
DAWN Stock Price History Chart
DAWN Stock Performance
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One …
Insider Activity of Day One Biopharmaceuticals, Inc.
Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $0 and sold $7.07M worth of Day One Biopharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $34.92M and sold $18.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.
List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.
| 2024-12-10 | Sale | HEAD OF R&D | 30,000 0.0301% | $13.31 | $399,339 | -3.40% | ||
| 2024-11-18 | Sale | HEAD OF R&D | 2,206 0.0022% | $13.21 | $29,142 | +2.61% | ||
| 2024-11-18 | Sale | COO, CFO AND SECRETARY | 2,602 0.0026% | $13.21 | $34,373 | +2.61% | ||
| 2024-11-18 | Sale | CHIEF EXECUTIVE OFFICER | 10,554 0.0106% | $13.21 | $139,420 | +2.61% | ||
| 2024-11-18 | Sale | GENERAL COUNSEL | 3,165 0.0032% | $13.21 | $41,810 | +2.61% | ||
| 2024-11-11 | Sale | HEAD OF R&D | 10,000 0.01% | $16.10 | $160,994 | -15.07% | ||
| 2024-11-08 | Sale | HEAD OF R&D | 18,255 0.0176% | $16.17 | $295,229 | -17.60% | ||
| 2024-11-07 | Sale | HEAD OF R&D | 11,245 0.0113% | $16.03 | $180,287 | -14.09% | ||
| 2024-10-31 | Sale | HEAD OF R&D | 500 0.0006% | $16.02 | $8,010 | -7.47% | ||
| 2024-09-10 | Sale | HEAD OF R&D | 30,000 0.0339% | $14.22 | $426,675 | -3.49% | ||
| 2024-08-16 | Sale | HEAD OF R&D | 2,232 0.0027% | $14.00 | $31,246 | 0.00% | ||
| 2024-08-16 | Sale | COO, CFO AND SECRETARY | 2,633 0.0031% | $14.00 | $36,860 | 0.00% | ||
| 2024-08-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,681 0.0127% | $14.00 | $149,524 | 0.00% | ||
| 2024-08-16 | Sale | GENERAL COUNSEL | 3,202 0.0038% | $14.00 | $44,825 | 0.00% | ||
| 2024-07-16 | Sale | HEAD OF R&D | 20,000 0.0273% | $16.01 | $320,226 | -12.99% | ||
| 2024-06-21 | Sale | director | 10,000 0.012% | $13.19 | $131,877 | +1.79% | ||
| 2024-06-10 | Sale | HEAD OF R&D | 30,000 0.0347% | $12.62 | $378,588 | +10.97% | ||
| 2024-05-16 | Sale | HEAD OF R&D | 2,267 0.0026% | $16.08 | $36,450 | -13.86% | ||
| 2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 7,873 0.009% | $16.08 | $126,588 | -13.86% | ||
| 2024-05-16 | Sale | COO, CFO AND SECRETARY | 2,675 0.0031% | $16.08 | $43,011 | -13.86% |
Insider Historical Profitability
| AI Day1 LLC | 10 percent owner | 12929322 12.8209% | $12.79 | 8 | 0 | +13.88% |
| Blavatnik Len | 10684638 10.595% | $12.79 | 1 | 0 | +23.65% | |
| Canaan XI L.P. | 10 percent owner | 8464301 8.3933% | $12.79 | 1 | 7 | <0.0001% |
| Atlas Venture Associates Opportunity I, LLC | 766667 0.7602% | $12.79 | 1 | 0 | +23.65% | |
| Gladstone Michael | 766667 0.7602% | $12.79 | 1 | 0 | +23.65% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $129.02M | 8.94 | 7.81M | 0% | +$0 | 0.13 | |
| Atlas Venture Life Science Advisors Llc | $106.23M | 7.36 | 6.43M | -15.48% | -$19.46M | 9.86 | |
| BlackRock | $83.12M | 5.76 | 5.03M | -1.85% | -$1.56M | <0.01 | |
| The Vanguard Group | $78.87M | 5.46 | 4.77M | +0.1% | +$78,255.24 | <0.01 | |
| Fidelity Investments | $72.76M | 5.04 | 4.4M | +10.99% | +$7.21M | 0.01 |